Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Platelet-activating factor antagonists: current status in asthma.

F P Gomez¹, R Rodriguez-Roisin

¹Respiratory Unit, Cardiology and Cardiovascular Surgery Institute, Favaloro University, Buenos Aires, Argentina.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy

|November 24, 2007

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Triflusal : A Viewpoint by F. Pérez Gómez.

Drugs·2016

Same author

GOLD and the fixed ratio.

The European respiratory journal·2011

Same author

Quality of life, stage severity and COPD.

The European respiratory journal·2009

Same author

[Phenotypic characterization and course of chronic obstructive pulmonary disease in the PAC-COPD Study: design and methods].

Archivos de bronconeumologia·2009

Same author

Adenosine 5'-monophosphate in asthma: gas exchange and sputum cellular responses.

The European respiratory journal·2008

Same author

Mitochondrial dysfunction in COPD patients with low body mass index.

The European respiratory journal·2006

Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

Same journal

Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

See all related articles

Platelet-activating factor (PAF) plays a role in asthma by causing inflammation and airway hyperresponsiveness. However, PAF receptor antagonists have shown limited success in treating asthma, suggesting further research is needed.

Area of Science:

Immunology
Pulmonology
Pharmacology

Background:

Platelet-activating factor (PAF) is a lipid mediator implicated in asthma pathogenesis.
PAF contributes to asthma symptoms like bronchoconstriction, mucus production, and airway hyperresponsiveness (AHR).
PAF attracts inflammatory cells such as eosinophils and neutrophils to the airways.

Purpose of the Study:

To review the role of Platelet-activating factor (PAF) in asthma.
To evaluate the efficacy of PAF receptor antagonists in managing asthma.
To explore future therapeutic strategies targeting PAF.

Main Methods:

Review of existing literature on PAF's role in asthma.
Analysis of clinical trial data for PAF receptor antagonists.

Related Experiment Videos

Discussion of PAF synthesis and degradation pathways.

Main Results:

PAF can induce key features of asthma, but its definitive role remains unclear.
PAF receptor antagonists have shown mixed results, with modest effects on allergen-induced responses and AHR.
Current PAF antagonists have not significantly impacted asthma treatment outcomes.

Conclusions:

The limited success of PAF receptor antagonists suggests extracellular PAF may not be a primary mediator or that antagonists are insufficient.
Further investigation into PAF's paracrine actions is warranted.
PAF synthase inhibitors could be valuable for understanding PAF's role and as future asthma therapeutics.